Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
IRIDEX Corporation is a medical devices business based in the US. IRIDEX Corporation shares (IRIX) are listed on the NASDAQ and all prices are listed in US Dollars. IRIDEX Corporation employs 89 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$7.41|
|52-week range||$1.60 - $8.97|
|50-day moving average||$7.40|
|200-day moving average||$7.32|
|Wall St. target price||$10.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.18|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||-6.56%|
|1 month (2021-09-17)||2.77%|
|3 months (2021-07-16)||17.81%|
|6 months (2021-04-16)||-3.89%|
|1 year (2020-10-16)||275.95%|
|2 years (2019-10-17)||292.06%|
|3 years (2018-10-17)||34.48%|
|5 years (2016-10-17)||12.82|
|Revenue TTM||$46.5 million|
|Gross profit TTM||$15.6 million|
|Return on assets TTM||-8.03%|
|Return on equity TTM||-11.01%|
|Market capitalisation||$117.3 million|
TTM: trailing 12 months
There are currently 137,055 IRIDEX Corporation shares held short by investors – that's known as IRIDEX Corporation's "short interest". This figure is 4.2% down from 143,102 last month.
There are a few different ways that this level of interest in shorting IRIDEX Corporation shares can be evaluated.
IRIDEX Corporation's "short interest ratio" (SIR) is the quantity of IRIDEX Corporation shares currently shorted divided by the average quantity of IRIDEX Corporation shares traded daily (recently around 47588.541666667). IRIDEX Corporation's SIR currently stands at 2.88. In other words for every 100,000 IRIDEX Corporation shares traded daily on the market, roughly 2880 shares are currently held short.
However IRIDEX Corporation's short interest can also be evaluated against the total number of IRIDEX Corporation shares, or, against the total number of tradable IRIDEX Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IRIDEX Corporation's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 IRIDEX Corporation shares in existence, roughly 10 shares are currently held short) or 0.0106% of the tradable shares (for every 100,000 tradable IRIDEX Corporation shares, roughly 11 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against IRIDEX Corporation.
Find out more about how you can short IRIDEX Corporation stock.
We're not expecting IRIDEX Corporation to pay a dividend over the next 12 months.
Over the last 12 months, IRIDEX Corporation's shares have ranged in value from as little as $1.6 up to $8.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while IRIDEX Corporation's is 1.2201. This would suggest that IRIDEX Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.